• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Hungary Pharmaceuticals and Healthcare Report Q1 2013 - Product Image

Hungary Pharmaceuticals and Healthcare Report Q1 2013

  • ID: 2373669
  • January 2013
  • Region: Hungary
  • 95 pages
  • Business Monitor International

FEATURED COMPANIES

  • Company Monitor
  • Domestic Manufacturers
  • Eli Lilly
  • Foreign Manufacturers
  • Gedeon Richter
  • GlaxoSmithKline
  • MORE

BMI View:

Our outlook for Hungary's pharmaceutical market remains negative, given the government's policies that shift the burden of the National Healthcare Fund (OEP) on to drug manufacturers. Pricing pressure and claw-back taxes have squeezed domestic manufacturers' margins and introduced insecurity to an already difficult economic environment, and we continue to expect a contraction in the size of the Hungarian pharmaceutical market in 2012 and 2013. Consequently, Hungarian drugmakers will have to become even more export-orientated. That said, a favourable tax regime for research and development should attract foreign investment, though these multinationals will focus most of their sales efforts on external markets, supporting our view that Hungary's status as a net exporter of pharmaceutical products will increase.

Headline Expenditure Projections:

- Pharmaceuticals: HUF691.61bn (US$3.44bn) in 2011 to HUF608.22bn (US$2.71bn) in 2012;
-12.1% in local currency terms and -21.2% in US dollar terms. Forecast down from Q412 due to cost-containment measures.

- Healthcare: HUF2,013bn (US$10.01bn) in 2011 to HUF2,003bn (US$8.92bn) in 2012; -0.5
%in local READ MORE >

FEATURED COMPANIES

  • Company Monitor
  • Domestic Manufacturers
  • Eli Lilly
  • Foreign Manufacturers
  • Gedeon Richter
  • GlaxoSmithKline
  • MORE

Executive Summary 5

SWOT Analysis 7

Hungary Pharmaceuticals And Healthcare Industry SWOT 7

Hungary Political SWOT 8

Hungary Economic SWOT 8

Hungary Business Environment SWOT 9

Pharmaceuticals Risk/Reward Ratings 10
Table: Central And Eastern Europe Pharmaceutical Risk/Reward Ratings, Q113 10

Rewards 11

Hungary - Market Summary 13

Regulatory Regime 14
Table: Marketing Authorisation Fees, 2011 14

Pharmaceutical Advertising 15

Intellectual Property Regime 16

Pricing Regime 18

Pharmaceutical Mark-ups 20
Table: Hungary - Pharmaceutical Price Build-Up (%) 21

Reimbursement Regime 21

Pricing and Reimbursement Amendments In 2011 and 2012 23
Table: Additional Savings Outlined in Szell Kalman 2 Plan Incorporating All Public Expenditure 24

Industry Developments 26

Epidemiology 26
Table: Leading Causes of Death, 2009 26

Communicable Disease 28

Healthcare System 29

Healthcare Funding 30
Table: Health Insurance Fund Expenditure by Type, 2004-2009 (HUF mn) 31

Public Pharmaceutical Expenditure 31

Medical Tourism 32

Research and Development 32

Clinical Trials 34

Medical Devices 35

Industry Forecast Scenario 37

Overall Market Forecast 37
Table: Pharmaceutical Sales Indicators, 2008-2016 39

Healthcare Market Forecast 40
Table: Healthcare Expenditure Indicators, 2008-2016 41
Table: Healthcare Governmental Indicators, 2008-2016 42
Table: Healthcare Private Indicators, 2008-2016 42

Key Growth Factors - Macroeconomic 43
Table: Hungary Long-Term Macroeconomic Forecasts 44

Prescription Drug Market Forecast 45
Table: Prescription Drug Sales Indicators, 2008-2016 46

Patented Drug Market Forecast 47
Table: Patented Drug Market Indicators, 2008-2016 48

Generic Drug Market Forecast 49
Table: Generic Drug Sales Indicators, 2008-2016 50

OTC Medicine Market Forecast 51
Table: OTC Medicine Sales Indicators, 2008-2016 52
Table: OTC Medicine Sales Sub-Indicators, 2005-2010 53

Pharmaceutical Trade Forecast 54
Table: Exports and Imports Indicators, 2008-2016 55

Medical Device Market Forecast 56
Table: Medical Devices Sales Indicators, 2008-2016 57

Other Healthcare Data Forecasts 58

Key Risks to BMI's Forecast Scenario 58

Competitive Landscape 59

Pharmaceutical Industry 59
Table: Members of MAGYOSZ, 2011 60
Table: Members of AIPM, 2011 60

Domestic Players 61
Table: Hungarian Pharmaceutical Production, 1990-2008 (HUF billions) 61

Foreign Players 62

Recent Company Activities 62

Pharmaceutical Wholesale 63

Pharmaceutical Retail 64
Table: Pharmacies, 2000-2010 64

Company Monitor 66

Domestic Manufacturers 66

Gedeon Richter 66

Egis Pharmaceuticals (Servier) 70

Foreign Manufacturers 73

Pfizer 73

Novartis 75

Sanofi 76

GlaxoSmithKline 78

Merck & Co 80

Eli Lilly 81

Teva 83

Country Snapshot: Hungary Demographic Data 85
Table: Hungary - Population By Age Group, 1990-2020 86
Table: Hungary -Population By Age Group, 1990-2020 87
Table: Hungary - Key Population Ratios, 1990-2020 88
Table: Hungary - Rural and Urban Population, 1990-2020 88

Glossary 89

BMI Methodology 91

How we Generate our Pharmaceutical Industry Forecasts 91

Risk/Reward Ratings Methodology 92

Ratings Overview 92
Table: Pharmaceutical Business Environment Indicators 93

Weighting 94
Table: Weighting Of Components 94

Company Monitor
Domestic Manufacturers
Gedeon Richter
Egis Pharmaceuticals (Servier)
Foreign Manufacturers
Pfizer
Novartis
Sanofi
GlaxoSmithKline
Merck & Co
Eli Lilly
Teva

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos